238 related articles for article (PubMed ID: 16495199)
1. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
2. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
3. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
Trotter CL; Gay NJ; Edmunds WJ
Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
De Wals P; Nguyen VH; Erickson LJ; Guay M; Drapeau J; St-Laurent J
Vaccine; 2004 Mar; 22(9-10):1233-40. PubMed ID: 15003652
[TBL] [Abstract][Full Text] [Related]
7. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
10. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
Borrow R; Miller E
Expert Rev Vaccines; 2006 Dec; 5(6):851-7. PubMed ID: 17184222
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
12. Expanding prevention of invasive meningococcal disease.
Pelton SI; Gilmet GP
Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
[TBL] [Abstract][Full Text] [Related]
13. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
14. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.
Trotter CL; Edmunds WJ; Ramsay ME; Miller E
Hum Vaccin; 2006; 2(2):68-73. PubMed ID: 17012888
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
Soriano-Gabarró M; Rosenstein N; LaForce FM
J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
[TBL] [Abstract][Full Text] [Related]
16. Meningococcal C conjugate vaccine: the experience in England and Wales.
Campbell H; Borrow R; Salisbury D; Miller E
Vaccine; 2009 Jun; 27 Suppl 2():B20-9. PubMed ID: 19477053
[TBL] [Abstract][Full Text] [Related]
17. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
[TBL] [Abstract][Full Text] [Related]
18. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
19. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation.
De Wals P; Trottier P; Pépin J
Vaccine; 2006 Apr; 24(17):3500-4. PubMed ID: 16517032
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
